
    
      The study objective is to determine if the administration of grazoprevir and elbasvir (with
      or without ribavirin) for 12-16 weeks after kidney transplantation prevents the spread of HCV
      infection from a donor kidney with known HCV genotype 1 or 4 infection to a HCV negative
      recipient as evidenced by a negative HCV viral RNA at 12 weeks post treatment
    
  